- Home
- GNLX vs CRBP Comparison
GNLX vs CRBP Comparison
Compare GNLX & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | CRBP |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.8M | 134.8M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GNLX | CRBP |
|---|---|---|
| Price | $2.66 | $9.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $19.75 | ★ $46.83 |
| AVG Volume (30 Days) | 150.4K | ★ 178.4K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.10 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $8,000.00 | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $99.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.99 | $4.64 |
| 52 Week High | $8.54 | $20.56 |
Technical Indicators
Market Signals| Indicator | GNLX | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 60.15 |
| Support Level | $2.54 | $9.08 |
| Resistance Level | $2.80 | $9.69 |
| Average True Range (ATR) | 0.17 | 0.60 |
| MACD | 0.02 | 0.26 |
| Stochastic Oscillator | 17.20 | 70.48 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.